Debrisoquine oxidation phenotype and neuroleptic‐induced dystonic reactions
- 1 November 1992
- journal article
- research article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 86 (5) , 364-366
- https://doi.org/10.1111/j.1600-0447.1992.tb03281.x
Abstract
To evaluate the role of defective drug oxidation as a predisposing factor for neuroleptic-induced dystonic reactions, 26 patients who developed the reaction and 53 with no history of dystonia were phenotyped by the debrisoquine hydroxylation test. The percentage of poor debrisoquine metabolizers was similar in patients with dystonic reactions (11.5%) and in the control group (9.4%). These results suggest that there is no association between the individual's drug oxidative status and the occurrence of neuroleptic-induced dystonia.Keywords
This publication has 22 references indexed in Scilit:
- Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation PhenotypeTherapeutic Drug Monitoring, 1992
- Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effectsEuropean Journal of Clinical Pharmacology, 1992
- Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humansActa Psychiatrica Scandinavica, 1991
- Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesiaSchizophrenia Research, 1991
- Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotypeClinical Pharmacology & Therapeutics, 1991
- Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beingsClinical Pharmacology & Therapeutics, 1989
- Adverse Effects of Antipsychotic AgentsDrugs, 1981
- Extrapyramidal reactions in adolescents treated with high-potency antipsychoticsAmerican Journal of Psychiatry, 1978
- Drug-induced dystoniaAmerican Journal of Psychiatry, 1975
- A Survey of Drug-Induced Extrapyramidal ReactionsJAMA, 1961